These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 31781989)

  • 1. Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein-protein interaction.
    Gureev M; Novikova D; Grigoreva T; Vorona S; Garabadzhiu A; Tribulovich V
    J Comput Aided Mol Des; 2020 Jan; 34(1):55-70. PubMed ID: 31781989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
    Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
    Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.
    Lauria A; Tutone M; Ippolito M; Pantano L; Almerico AM
    Curr Med Chem; 2010; 17(28):3142-54. PubMed ID: 20666726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.
    Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y
    Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2,4,5-Tris(alkoxyaryl)imidazoline derivatives as potent scaffold for novel p53-MDM2 interaction inhibitors: Design, synthesis, and biological evaluation.
    Bazanov DR; Pervushin NV; Savitskaya VY; Anikina LV; Proskurnina MV; Lozinskaya NA; Kopeina GS
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2364-2368. PubMed ID: 31196710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy.
    Li J; Wu Y; Guo Z; Zhuang C; Yao J; Dong G; Yu Z; Min X; Wang S; Liu Y; Wu S; Zhu S; Sheng C; Miao Z; Zhang W
    Bioorg Med Chem Lett; 2014 Jun; 24(12):2648-50. PubMed ID: 24813735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
    Sirous H; Chemi G; Campiani G; Brogi S
    Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of High Affinity Non-Peptidic Small Molecule Inhibitors of MDM2-p53 Interactions through Structure-Based Virtual Screening Strategies.
    Bandaru S; Ponnala D; Lakkaraju C; Bhukya CK; Shaheen U; Nayarisseri A
    Asian Pac J Cancer Prev; 2015; 16(9):3759-65. PubMed ID: 25987034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular interaction fields and 3D-QSAR studies of p53-MDM2 inhibitors suggest additional features of ligand-target interaction.
    Dezi C; Carotti A; Magnani M; Baroni M; Padova A; Cruciani G; Macchiarulo A; Pellicciari R
    J Chem Inf Model; 2010 Aug; 50(8):1451-65. PubMed ID: 20726601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode.
    Gessier F; Kallen J; Jacoby E; Chène P; Stachyra-Valat T; Ruetz S; Jeay S; Holzer P; Masuya K; Furet P
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3621-5. PubMed ID: 26141769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.
    Wang S; Zhao Y; Aguilar A; Bernard D; Yang CY
    Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28270530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening.
    Atatreh N; Ghattas MA; Bardaweel SK; Rawashdeh SA; Sorkhy MA
    Drug Des Devel Ther; 2018; 12():3741-3752. PubMed ID: 30464405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 2.
    Wang W; Lv D; Qiu N; Zhang L; Hu C; Hu Y
    Bioorg Med Chem; 2013 Jun; 21(11):2886-94. PubMed ID: 23611770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Effective Virtual Screening Protocol To Identify Promising p53-MDM2 Inhibitors.
    Tortorella P; Laghezza A; Durante M; Gomez-Monterrey I; Bertamino A; Campiglia P; Loiodice F; Daniele S; Martini C; Agamennone M
    J Chem Inf Model; 2016 Jun; 56(6):1216-27. PubMed ID: 27269808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1.
    Wang W; Shangguan S; Qiu N; Hu C; Zhang L; Hu Y
    Bioorg Med Chem; 2013 Jun; 21(11):2879-85. PubMed ID: 23601819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic.
    Carry JC; Garcia-Echeverria C
    Bioorg Med Chem Lett; 2013 May; 23(9):2480-5. PubMed ID: 23541651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Group-based QSAR and molecular dynamics mechanistic analysis revealing the mode of action of novel piperidinone derived protein-protein inhibitors of p53-MDM2.
    Goyal S; Grover S; Dhanjal JK; Tyagi C; Goyal M; Grover A
    J Mol Graph Model; 2014 Jun; 51():64-72. PubMed ID: 24858256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small-molecule MDM2-p53 inhibitors: recent advances.
    Zhang B; Golding BT; Hardcastle IR
    Future Med Chem; 2015; 7(5):631-45. PubMed ID: 25921402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Unique Mdm2-Binding Mode of the 3-Pyrrolin-2-one- and 2-Furanone-Based Antagonists of the p53-Mdm2 Interaction.
    Surmiak E; Twarda-Clapa A; Zak KM; Musielak B; Tomala MD; Kubica K; Grudnik P; Madej M; Jablonski M; Potempa J; Kalinowska-Tluscik J; Dömling A; Dubin G; Holak TA
    ACS Chem Biol; 2016 Dec; 11(12):3310-3318. PubMed ID: 27709883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening of medicinal plant phytochemicals as natural antagonists of p53-MDM2 interaction to reactivate p53 functioning.
    Riaz M; Ashfaq UA; Qasim M; Yasmeen E; Ul Qamar MT; Anwar F
    Anticancer Drugs; 2017 Oct; 28(9):1032-1038. PubMed ID: 28723868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.